Achillion Pharma (ACHN) Announces Two Side Effects Observed in MAD Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Chardan Capital Markets Upgrades Achillion Pharmaceuticals (ACHN) to Neutral Following Underperformance
November 4, 2016 6:33 AM EDTChardan Capital Markets upgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Sell to Neutral with a price target of $5.00 share price underperformance relative to the XBI in the past three and a half months. The upgrade come ahead of 1H17 clinical catalysts in the multiple ascending dose (MAD) study of ACH-4471.
Analyst Madhu Kumar commented, "Over the past three and a half months (from market close 13 July to market close 3 November),... More
Leerink Maintains Achillion Pharma (ACHN) at 'Market Perform'; Says MAD Study Questions Raised
November 3, 2016 11:55 AM EDTLeerink affirms Achillion Pharma (NASDAQ: ACHN) at Market Perform following Q3 results and update issued earlier Thursday.
The firm commented today: We believe today's stock weakness is related to caution due to ACHN's disclosure of two cases of liver enzyme elevations in the ongoing multiple ascending dose (MAD) Phase I study of ACH-4471. This update was mentioned... More
Buy Achillion Pharmaceuticals (ACHN) on Sell-Off - Baird
November 3, 2016 11:53 AM EDTBaird analyst Brian Skorney is telling clients to buy Achillion Pharmaceuticals (NASDAQ: ACHN) on today's sell-off. The firm reiterated an Outperform rating and price target of $10.
Skorney commented, "The market for biotech has completely broken down and with it, Achillion's... More
Achillion Pharmaceuticals (ACHN) Sell Rating Reiterated at Chardan Capital Markets Amid ACH-4471 Risks
November 3, 2016 11:16 AM EDTChardan Capital Markets analyst Madhu Kumar reiterated a Sell rating and $5 price target on Achillion Pharmaceuticals (NASDAQ: ACHN) saying ACH-4471 liver signals and developmental delays pose risks.
Kumar commented, "This morning, Achillion Pharmaceuticals (Sell) announced 3Q16 earnings results and updates on clinical... More
Achillion Pharma (ACHN) Reports Q3 Loss of $0.15
November 3, 2016 9:03 AM EDTAchillion Pharma (NASDAQ: ACHN) reported Q3 EPS of ($0.15), versus ($0.16) reported last year.
For earnings history and earnings-related data on Achillion Pharma (ACHN) click here.
... More
